Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224
Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Guggenheim revised the price target on Krystal Biotech, Inc.
Krystal Biotech Inc. (KRYS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,888,888 | $712,226,448 | +4% | 7% |
| 2. | Soleus Capital Guy Levy | 941,059 | $232,008,686 | -8% | 8.56% |
| 3. | Redmile Group Jeremy Green | 677,705 | $167,081,391 | +3% | 12.3% |
| 4. | Hood River Capital Management David Swank | 613,302 | $151,203,475 | +2% | 1.66% |
| 5. | Citadel Investment Group Ken Griffin | 386,505 | $95,288,943 | -40% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 25,000 | $500,000.00 | 2,001,462 | 2018-10-18 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 2,036,462 | 2018-10-18 | Filing | |
| $12.45 | 1,018 | $12,674.10 | 1,976,462 | 2018-06-06 | Filing | |
| $11.15 | 13,116 | $146,177.82 | 1,975,444 | 2018-06-06 | Filing | |
| $10.75 | 10,866 | $116,757.34 | 1,962,328 | 2018-06-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $266.42 | 1,700 | $452,918.08 | 1,403,155 | 2026-03-04 | Filing | |
| $265.16 | 6,000 | $1,590,979.20 | 1,404,855 | 2026-03-04 | Filing | |
| $264.64 | 4,852 | $1,284,019.21 | 1,410,855 | 2026-03-04 | Filing | |
| $263.58 | 2,248 | $592,534.81 | 1,415,707 | 2026-03-04 | Filing | |
| $262.35 | 1,938 | $508,430.23 | 1,417,955 | 2026-03-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,349,628 | $1,072,357,209 | 0.05% | |
| 2. | 3,937,817 | $970,829,404 | 0.02% | |
| 3. | 2,778,845 | $685,096,446 | 0.01% | |
| 4. | 1,342,303 | $330,931,382 | 0.01% | |
| 5. | 809,500 | $199,574,130 | 0.03% |
News See All
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
On February 23, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and tariff uncertainties.
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating
On February 17, 2026, Jefferies analyst Roger Song raised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $371 from $310 and maintained a Buy rating.
11 Best All-Time High Stocks to Buy According to Wall Street
When stock prices are breaking records, the instinct is often to wait for a pullback. But history suggests that hesitation can be costly.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Krystal Biotech, Inc. 4Q 2025 Conference Call. At this time, all participants are on a listen-only mode.
10 Best NASDAQ Growth Stocks to Buy for the Next 10 Years
The AI trade has become overcrowded, and with the exception of Google and Nvidia, the Mag 7 stocks haven’t even managed to beat the S&P 500 index in 2025.
What Does Wall Street Think About Krystal Biotech (KRYS)?
Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best strong buy growth stocks to buy according to hedge funds. On January 12, Citi lifted the price target on Krystal Biotech, Inc.
11 Best Strong Buy Growth Stocks to Buy According to Hedge Funds
She stated that one of the significant things the last few years have taught her is that while inflation is clearly coming down, it is stuck in the reported numbers.
Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT
Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Hedge Fund Resource Center